Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
About this episode
The episode discusses the role of KIT-targeted TKIs in treating indolent systemic mastocytosis, featuring expert insights on current and emerging therapies.
Faculty: Mariana C. Castells, MD, PhD Faculty: Tsewang Tashi, MD This online educational activity explores the evolving role of KIT-targeted tyrosine kinase inhibitors (TKIs) in indolent systemic mastocytosis (ISM). Expert faculty discuss pivotal clinical data supporting the approval of avapritinib, a potent TKI that targets KIT D816V, in patients with ISM. They also highlight emerging clinical evidence on next-generation KIT TKIs, such as elenestinib and bezuclastinib, that are designed for enhanced selectivity and minimal brain penetration. Finally, faculty discuss how these agents may be sequenced and integrated into a personalized, multidisciplinary treatment approach aimed at durable symptom control and improved quality of life for patients with ISM.
People in this episode
Guests: Mariana C. Castells, MD, PhD, Tsewang Tashi, MD
Mentioned in this episode
Products: avapritinib
More episodes of CME
- Counseling Patients on Their Future with Biologics
- Safety in oHCM Therapy: How and When to Transition Treatment?
- Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
- Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
- Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
- The Future of HNSCC: Aligning Teams, Transforming Care
Explore listener stats, chart rankings, contacts and more on the CME podcast page.